Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1164-8495

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the effect of once-weekly dosing of two dose levels of subcutaneous semaglutide (0.5 mg and 1.0 mg) versus once-weekly dosing of two dose levels of subcutaneous dulaglutide (0.75 mg and 1.5 mg) on glycaemic control in subjects with type 2 diabetes on a background treatment with metformin.


Critère d'inclusion

  • Diabetes Mellitus, Type 2